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Overview of the Thesis 
 
Background of the Study 
 
Subclinical hypothyroidism and hyperthyroidism have been associated with an increased risk 
of acute coronary syndrome and mortality. Factors contributing to this association include; a 
high concentration of total cholesterol and increased risk of atherosclerosis and altered 
cardiovascular hemodynamics.(1) Several studies have shown that overt hypothyroidism is 
strongly associated with all components of coronary artery disease (CAD) but studies relating 
to the relationship between subclinical hypothyroidism and CAD has not been given much 
consideration.(1) Hypothyroid patients may have a high concentration of creatinine kinase 
(CK) mostly due to a rise in creatinine kinase MM (CK-MM) which may also lead to high 
levels of creatinine kinase BB (CK-MB). Therefore, this may cause confusion in the 
evaluation and diagnosis of myocardial injury in a hypothyroid patient presented with chest 
pain.   
 
 Troponin I is a superior indicator to diagnose myocardial injury, but case reports of 
hypothyroid patients with increased Troponin I suggest that hypothyroidism might be a risk 
factor for myocardial injury and increase risk of cardiac death.(2) Hypothyroidism might also 
lead to hypercoagulability, endothelial dysfunction, hyperhomocysteinemia, impaired 
fibrinolysis, systemic inflammation and platelet abnormalities and these are considered as 
risk factors for CAD.(2) Changes in thyroid hormone values in the plasma are linked to 
higher mortality in patients with acute myocardial infarction suggesting a role for thyroid 
hormone signalling in post-ischemic cardiac recovery. This hypothesis was done in 
experimental models of ischemia- reperfusion and myocardial infarction in animals and 
accumulating evidence reveals that thyroid hormones are critical for the response of the 
myocardium to ischemic stress and that thyroid hormones may have cytoprotective properties 
that are not evident in healthy tissue and appear only during stress. This hypothesis was 
developed in 2011 on 67 patients, 12 of those patients who had altered thyroid hormone 
values.(2) 
 
 Acute myocardial infarctions represent a major public health problem despite improvements 
in reperfusion therapy. The 2020 World Health Organization (WHO) projections view the 
high incidence of post-ischemic heart failure as the most important cause of morbidity and 
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mortality.(2) Therefore, thyroid hormones are increasingly being recognized as significant 
players in the pathogenesis, recovery and repair period of acute myocardial infarction. 
Likewise, study findings of subclinical hypothyroidism and hyperthyroidism showed an 
increase in the point estimates for coronary heart disease and mortality. 
Aim of the Study 
The study aims to retrospectively look at patients presenting with a myocardial infarction 
(MI) and: : 
 
 To determine if there was a difference between the demographic status (age, gender 
and ethnicity) of patients presenting with normal and abnormal thyroid function tests 
 To determine if the inpatient’s mortality and morbidity as measured by clinical 
improvement differ according to the patient’s thyroid status. 
 To calculate if there was an association between the thyroid state and conventional 
cardiovascular risk factors such as age, blood pressure, lipids (total cholesterol), 
measured blood glucose and patients' pulse rate. 




A cross-sectional study design was applied utilising a convenience sample of 79 patients 
presenting with an acute coronary syndrome (ACS) and available thyroid function test 
results , which are taken routinely,  who were admitted during the period of January 2010 to 
September 2018. The three categories (hyperthyroidism, hypothyroidism and normal 
euthyroid) were identified in association with an acute coronary syndrome. Demographic 
status ,Age, gender and ethnicity, of the patients were documented as were the  the presence 
of conventional cardiac risk factors. Sequential patients were sampled once the number of 
euthyroid patients was identified. Likewise, the selection of specific patients with thyroid 
dysfunction continued until a sufficient sample size for predetermined statistical analysis was 
obtained. Participants included in the sample were over 18 years of age. 
The research location was based at Addington Hospital which serves an urban population in 
central Durban. The demographic and clinical information about the population sample for 
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the study was accessed from a hard copy database and was entered into the data collection 
sheet. Data were processed using IBM SPSS Version 24.0. An abnormal thyroid state was 
defined as hypothyroidism, a TSH greater than 5.50mIU/L with a FT4 less than 11.5pmol/L 
or hyperthyroid state as a TSH less than 0.35Miu/l and a FT4 greater than 22.7pmol/L. 
Conventional cardiovascular risk factors that were used in multivariate analysis included the 
patients’ age, total cholesterol, triglyceride, HDL, pulse rate and blood pressure. The area of 
infarcted tissue was also compared to the patients’ thyroid function.  
The following were considered during data analysis: 
 Fisher’s exact and chi-square were used to test the significant difference between 
Acute Coronary Syndrome outcomes and thyroid dysfunction 
 To determine the risk of having a thyroid abnormality for each race, a multinomial 
regression was conducted showing the relative risk for each variable by thyroid type 
using euthyroid patients as the referent group.  
 A multinomial logistic regression was done to identify risk factors due to the thyroid 
state. The model included single variables as independent variables to identify the 
most statistically significant variable for the multiple regression. 
 
Furthermore, ethical approval was obtained from the University of KwaZulu-Natal (UKZN) 
Biomedical Research and Ethics Council (BREC) Ethics Committee (BE 454/17). Permission 
to conduct the research was granted by Addington Hospital. Confidentiality and anonymity of 
patients were maintained and there was no specific mention of any patient’s personal 
information (such as names, birth dates, identification number and hospital number). The 
study was completely retrospective and non-interventional.  
Result 
Black patients were significantly more likely to be hypothyroid when presenting with a 
myocardial infarction. There was no significant correlation between thyroid function and 
conventional risk factors in all other groups studied. 
Conclusion 
There was no significant difference between conventional risk factors with both hypothyroid 
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 Review of Literature 
The synthesis of thyroxin (T4) and Triiodothyronine (T3) in the thyroid gland is activated by 
thyroid-stimulating hormone (TSH). Almost 85% of T4 is primarily secreted by the thyroid 
gland and then converted in the liver, kidney, and skeletal muscles to T3 by the enzyme 5’-
mono-deiodinase.(2) Reverse T3 (rT3) is a biologically inactive alternate product of T4 
deiodination. Only a small fraction of the thyroid hormones is unbound and biologically 
active because most of the circulating thyroid hormones are bound to transport proteins. T4, 
T3 and TSH changes have been considered  as one of the risk events of the cardiovascular 
system, mainly due to the physiological metabolism of alteration  of oxygen consumption and 
changes in carbohydrate, lipid and protein metabolism.(2) Thyroid hormones have an effect 
on gene encoding in the regulation of the myocardium and thyroid hormones also play a role 
in cardiovascular haemostasis. Hypothyroidism causes dynamic changes in cardiovascular 
function such as a decrease in left ventricular contraction which leads to a decrease in cardiac 
output.(2) 
The role of subclinical hypothyroidism in ischemic heart disease was first suggested by 
Bastenie et al.(3) It was suggested that hypothyroidism had a role in atherosclerosis and the 
derangement of risk factors of coronary artery disease. The presence of atherosclerosis in 
hypothyroidism was most likely secondary to associated hypertension, hypercholesterolemia 
and hyperhomocysteinemia.(3) Acute coronary syndromes (ACS) are high-risk 
manifestations of coronary atherosclerosis and acute myocardial ischemia. Disruption of a 
coronary atherosclerotic plaque with subsequent thrombus formation is the main 
pathophysiology of such an event, which triggers an immediate inflammatory cascade. 
Inflammation seems to play a key role in plaque disruption, which stimulates thrombosis, 
coagulation, activation of the sympathetic system, and release of stress hormones. 
Normal thyroid homeostasis seems to change in a subgroup of patients with ACS. Several 
studies have observed a fall in total T3 and/or fT3 concentration and a rise in rT3 
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concentration after an acute coronary event.(3,4) The exact prevalence of the low T3 
syndrome among patients suffering an ACS seems not to be clearly defined yet. Although 
studies have reported that a wide range from 5% to 35% and this could be attributed to 
differences in study populations between the conducted studies. However, the syndrome 
seems to occur more frequently in ST-elevation myocardial infarction (STEMI) patients 
compared with non-ST-elevation myocardial infarction (NSTEMI) patients, possibly because 
of poor early prognosis and the pathophysiologic features of the occlusive thrombus resulting 
in more myocardium at stake.(4)  
The acute effects of cytokines seem to play a key role in the pathogenesis of low T3 
syndrome. It has been reported that the administration of interferon-α in healthy volunteers 
can cause disturbances in TH metabolism, mimicking the syndrome.(5) During critical illness, 
various pro-inflammatory cytokines such as interleukin 6 (IL- 6), tumor necrosis factor-α 
(TNFα), and interferon-γ (IFγ) can directly affect the pituitary gland and impair TSH release. 
Concerning patients with ACS, THs alterations are supposed to develop through the 
inflammatory response activation. Increases in IL-6, a pleiotropic, proinflammatory cytokine; 
soluble IL-6 receptor (sIL-6R); and C-reactive protein (CRP) levels may exert an inhibitory 
effect on thyroid axis function.  
The occurrence of decreased thyroid hormones levels during an ACS has been associated 
with various clinical studies with specific clinical and biochemical parameters.(5) Worsened 
angina pectoris preceding the acute myocardial infarction (AMI) known as chronic heart 
failure, or previous myocardial infarction (MI) and diabetes mellitus (DM) have been linked 
to lower T3 levels during the acute coronary event.(5) In general, although, the available 
evidence is not strong, factors that seem to be associated with the development of low T3 
syndrome among patients with ACS include older age, lower body mass index, DM, and high 
plasma levels of N-terminal pro-brain natriuretic peptide and CRP. 
The first meta-analysis study was published in 2008 which showed a significant association 
between hypothyroidism and coronary artery disease (CAD) with relative risk RR of 1.533. A 
second meta-analysis reported the same result with RR of 1.20.(6) T3 which is the most 
important bioactive thyroid hormone for cardiomyocytes is mostly produced by a process of 
deiodination of T4. It can affect cardiomyocytes via genome and non-genome action. T3 
regulates transcription by binding hormone receptors (TRs) in the nucleus, which then binds 
thyroid hormone response elements (TREs) present in regulatory regions of target genes. 
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Non-genome actions of T3 include thyroid hormone signalling, changes in thyroid hormone 
levels, and changes in thyroid hormone receptor TRα1 can limit myocardial injury and post-
ischemic cardiac remodelling through T3 binding.(6) This regulates genes related to 
contractile protein, pacemaker activity and conduction, cell growth, differentiation and 
metabolism. Also, thyroid hormones could affect cardiac apoptosis through the suppression 
of ischemia reperfusion-induced activation of the pro-apoptotic P38 mitogen-activated 
protein kinase (MAPK) and up-regulation of cardio-protective molecules such as heat shock 
protein 27 (HSP27) and heat shock protein 70 (HSP70), which are also involved in ischemic 
preconditioning.(6) More so, T3 may regulate plasma membrane ion currents, activate 
survival pathways, and decrease oxidative stress in mitochondria.(7) Therefore, heart rate, 
cardiac contractility, vascular smooth muscle and endothelial function will be modulated. 
When T3 is low, a negative effect on cardiovascular system will occur.(7) Clinical studies 
also confirmed that low T3 was associated with larger thrombus burden, higher severity of 
coronary artery lesions and larger myocardial injury size in ACS patients.(8) 
The close link between thyroid hormonal status and cardiovascular diseases is evident by the 
significant effects of thyroid dysfunction, both subclinical and overt, on the cardiovascular 
system. On the one hand, hypothyroidism is correlated with diastolic hypertension, 
dyslipidemia, atherosclerotic plaque progression and instability, and endothelial 
dysfunction .(9) On the other hand, hyperthyroidism is associated with increased systolic 
blood pressure, pulmonary hypertension, and atrioventricular valve regurgitation, especially 
of the tricuspid valve 8. In rare cases, patients with overt hyperthyroidism and thyrotoxicosis 
can be presented with chest pain and ECG abnormalities due to increases in oxygen demands 
in response to augmented cardiac contractility and workload or due to coronary vasospasm.(9)  
Moreover, patients with hyperthyroidism can be presented with signs and symptoms of heart 
failure characterized by enhanced cardiac output and contractility. Heart rhythm and rate may 
be significantly affected by even mildly altered thyroid status.(10) The arrhythmogenic 
effects of THs include altered electrophysiological characteristics of atrial myocytes, 
enhanced automaticity, triggered activity in pulmonary vein cardiomyocytes, and shortened 
action potential duration.  Arrhythmias such as sinus tachycardia, atrial flutter, and atrial 
fibrillation, and to a lesser extent, ventricular arrhythmias are commonly found in patients 
with overt or mild subclinical hyperthyroidism.(10) 
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Hypothyroidism is correlated with sinus bradyarrhythmias and various ECG abnormalities. 
Several clinical and experimental studies have suggested potential anti-proarrhythmic effects 
of the THs and a direct effect on electrogenesis in myocardial cells.(11,12) Alterations in TH 
plasma concentrations during a variety of acute and chronic illnesses in patients with 
unknown intrinsic thyroid disease are described by various terms such as “euthyroid sick 
syndrome,” “nonthyroidal illness syndrome,” and “low T3 syndrome.” (12)  The most 
frequently observed hormonal profile is characterized by low T3 and/or fT3, elevated rT3 and 
normal T4 and TSH. The principal pathophysiological mechanism is supposed to be the 
reduced activity of the enzyme 5’-monodeiodinase, which converts T4 to T3. The euthyroid 
sick syndrome seems to be a timing-related organ-specific response to inflammation during 
various critical illnesses and constitute an adaptive, compensatory, beneficial response, and 
decreasing energy consumption. However, it has been linked to worse prognosis and 
increased mortality in patients with septic shock or acute stroke. Acute cardiac diseases also 
have been associated with low serum T3 levels.(13, 14) It has been reported that THs 
alterations constitute a powerful independent marker of the severity of illness and mortality in 
patients after resuscitated cardiac arrest. Similarly, lower serum fT3 levels were reported as a 
strong predictor of mortality in all cardiac patients, with both acute and chronic diseases, as 
stable coronary artery disease or congestive heart failure.(14) 
Subclinical hypothyroidism and hyperthyroidism have been associated with an increased risk 
of ACS’s and mortality. Factors contributing to this association include; an increase 
concentration of total cholesterol (15, 16) and increase the risk of atherosclerosis, (17,18) and 
altered cardiovascular hemodynamics.(19,20,21,22,23,24) Overt hypothyroidism has been 
proven to be strongly associated with all components of coronary artery disease (CAD) but 
the relationship between subclinical hypothyroidism and CAD has not been partially proven 
in different studies.(24-25) Hypothyroid patients may have a high concentration of creatinine 
kinase mostly due to an increase in CK-MM which may also lead to high levels of CK-MB. 
This may cause confusion in the evaluation and diagnosis of myocardial injury in a 
hypothyroid patient presented with chest pain. The Troponin I is a superior indication to 
diagnose myocardial injury, but case reports of hypothyroid patients with an increased 
Troponin I suggest that hypothyroidism might be a risk factor for myocardial injury and 




Hypothyroidism might also lead to hypercoagulability, endothelial dysfunction, 
hyperhomocysteinemia, impaired fibrinolysis, systemic inflammation and platelet 
abnormalities, all risk factors for CAD.(31) The changes in thyroid hormone values in the 
plasma are linked to higher mortality in patients with acute myocardial infarction suggesting 
a role for thyroid hormone signalling in post-ischemic cardiac recovery. This hypothesis was 
done in experimental models of ischemia-reperfusion and myocardial infarction in animals 
and accumulating evidence reveals that thyroid hormones are critical for the response of the 
myocardium to ischemic stress and that thyroid hormones may have cytoprotective properties 
that are not evident in healthy tissue and appear only during stress. This hypothesis was 
developed in 2011 on 67 patients, 12 of the patients had altered thyroid hormone values.(32) 
Furthermore, during experimental coronary artery ligation in an animal model of acute 
myocardial infarction, heart failure was found to be associated with the reduction of thyroid 
hormones receptor expression in the myocardium, leading to tissue hypothyroidism. The 
administration of Thyroid hormones improved cardiac contractility, augmented myocardial 
remodeling and improved left ventricular function. Thyroid hormones also regulate 
angiogenesis, cardio-protection, cardiac metabolism, and myocyte regeneration at a 
molecular level. In addition, thyroid hormones regulate changes that can reverse left 
ventricular remodeling by improving myocyte shape and geometry of the left ventricular 
cavity, then improving recovery from acute myocardial infarction.(33)  
Acute myocardial infarctions represent a major public health problem despite improvements 
in reperfusion therapy. The 2020 World Health Organization (WHO) projections view the 
high incidence of post-ischemic heart failure as the most important cause of morbidity and 
mortality. In this regard, thyroid hormones are increasingly being recognized as significant 
players in the pathogenesis, recovery and repair period of acute myocardial infarction.(34) 
Moreover, both subclinical hypothyroidism and hyperthyroidism reviewed showed an 
increase in the point estimates for coronary heart disease and mortality.(35) A study was done 
at the hospital of China Medical University, to look at outcomes of patients with ACSs and 
mild thyroid function abnormalities. The study found a significantly increased risk of all-
causes of mortality with patients who had low T3 but not subclinical hypothyroidism or 
hyperthyroidism compared to euthyroid patients.(36)  
Similarly, a study conducted in Nepal in 2017 regarding abnormal thyroid hormone profile 
related to gender and age group. Findings from this study showed that 27.5% of males had an 
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abnormal thyroid hormone profile and 21.4% of Females had an abnormal thyroid hormone 
profile. There was no statistically significant difference in the prevalence of abnormal thyroid 
profiles (P=0.322). It was accounted that 56% were in the age group of above 60 years, 36% 
were in the age group of 40-60 years and 8% were in the age group of 20-40 years.(37) 
Experimental data suggest a critical role for THs in the response of myocardium to ischemic 
stress. Few clinical studies involving patients with AMI have addressed the possible 
correlation of THs with the extent of myocardial injury. Lower fT3 levels have been 
associated with increased serum levels of cardiac biomarkers (troponin T and N-terminal pro-
brain natriuretic peptide) as indicators of myocardial injury, as well as with lower left 
ventricular ejection fraction.(38,39)  
In addition, studies (40) have reported a strong association of low T3 with impaired 
ventricular function among AMI patients, concluding that T3 levels may represent a predictor 
of ventricular functional recovery. Interestingly, the findings of another study (41) exhibited 
that the extent of transmural involvement in patients with STEMI, assessed by cardiac 
magnetic resonance imaging 40 days after the event, is strongly associated with T3 levels. In 
this retrospective and small-sized study, the group with high/normal T3 levels had a 
significantly greater extent of transmural involvement than the low-T3 group, which 
presented a significantly larger myocardial area at risk. Thus, a greater extent of ischemia and 
an increased myocardial salvage index. 
The findings also revealed that the transient low T3 state during acute myocardial infarction 
is associated with lower transmurality, suggesting a protective role of the low T3 syndrome. 
Putting it all together, the existing data indicate that the link of the low T3 syndrome to worse 
prognosis and mortality among patients suffering an acute myocardial infarction is not 
necessarily reflected in the possible correlation of the syndrome with the extent of myocardial 
necrosis. Large initial myocardial ischemia can result in worse short-term prognosis, whereas 
large transmurality can result in worse long-term prognosis.(41) 
Although, thyroid hormone plasma alterations have been studied more extensively in STEMI 
patients, they can occur in all aspects of ACS. However, it is important to emphasize that the 
low T3 syndrome is evident in a small group of ACS patients that seem to have a worse 
outcome. In the absence of robust data derived by large-scale clinical studies, it remains 
unclear whether the low T3 syndrome is directly linked to worse prognosis or it constitutes a 
marker of the severity of illness, which is the underlying factor for increased mortality.(42) 
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However, the syndrome should not be underestimated, as disturbances of T3, fT3, and rT3 
levels seem to carry an additive prognostic value in ACS, independently of traditional risk 
factors. In this setting, although the exact timing of thyroid hormones alterations seems not to 
be clearly defined yet, routine determination of plasma levels of thyroid hormones among 
patients suffering an ACS might reveal an otherwise silent prognostic marker.  
Nevertheless, further high-quality studies need to confirm this, and additional research is 
needed to clarify when and how this potentially powerful prognostic marker could be 
operationalized in the clinical setting. All available data indicate that alterations in thyroid 
function tests are not uncommon in patients with ACS, especially in STEMI patients.(42) The 
low T3 syndrome represents a hormonal imbalance that may significantly influence 
pathophysiological mechanisms and cardiovascular hemodynamics. This altered thyroid state, 
and more specifically, the fall of T3 and/or fT3 and the rise of rT3 seem to be related to 
overall worse prognosis, and it could be useful in the prognostic stratification of patients 
suffering an ACS.(42) 
There are central and peripheral effects of thyroid hormones on glucose metabolism and lipid 
metabolism regulated by insulin secretion and insulin sensitivity on different tissues. In 
hypothyroidism, there is slow glucose gastrointestinal absorption, retardation of 
gluconeogenesis, and glucose utilization peripherally with a consequent increase of insulin 
resistance.(42) Hypothyroidism will alter glycemic and lipid profiles of the patients with 
prediabetes and will aggravate the course of the disease in those with already known 
diabetes.(43)  
Hyperthyroidism due to a toxic nodular goiter is responsible for increased insulin degradation, 
increased glucagon secretion, and increased hepatic glucose production, all these factors 
aggravate the glycemic control in diabetic patients.(44) On the other hand, patients with 
noncontrolled hyperthyroidism and hypothyroidism showed worsened lipidemic 
profile.(44,45) In these cases, the coexistence of abnormal glycemic and lipid profiles could 
be the onset of acute coronary syndrome.(46) Hypothyroid patients might exhibit elevated 
HDL cholesterol levels mainly due to increased concentration of HDL particles, and also 
because of the decreased activity of cholesteryl ester transfer protein (CETP).(47) 
Dyslipidemia has been established as a well-known risk factor for cardiovascular disease 
(CVD) in chronic kidney disease (CKD) and large-scale observational studies have shown 
that total and LDL cholesterol is the most important independent predictors of cardiovascular 
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morbidity and mortality.(48) Thyroid dysfunction and dyslipidemia in CKD may further 
increase CVD risk leading to increased morbidity and mortality. Therefore, early diagnosis 
and treatment of thyroid and lipid disorders in CKD may slow the progression of CKD in 
























The study was conducted in Addington hospital that serves an urban population in central 
Durban in South Africa. Addington hospital is the first functional hospital in Durban and was 
named after Rt. Hon. Henry Addington who held the post of prime minister of Great Britain 
in 1801. The hospital was officially opened on 10 November 1967 and its priority is to 
promote good service, adhere to service standards and recognition of high performing 
staff.(50) 
Study design 
Research design can be considered as the structure of research. It is the glue that holds all of 
the elements in a research project together, in short, it is a plan of the proposed research 
work.(51) This study adopted a cross-sectional study design utilising a convenience sample 
of 79 patients presenting with acute coronary syndrome (ACS).  
Study population 
Robson (52) defines a population as a universe of elements from which the sample elements 
are drawn. It can be literal population (that could be a number of people) but it is also used 
more specifically (for example, it could be the population of all hospitals in the region). The 
study population targets patients admitted to Addington Hospital. The study utilised a 
convenience sample of 79 patients with acute coronary syndrome and thyroid dysfunction 





The study sample randomly selected 79 patients with ACS and thyroid dysfunction. The three 
categories (hyperthyroidism, hypothyroidism and normal euthyroid) were investigated in 
association with ACS. As a result, patients were divided into three groups namely: 
 Group 1- included 27 hypothyroid patients  
 Group 2 -included 27 euthyroid patients  
 Group 3 - included 25 hyperthyroid patients 
Demographic status (Age, gender, and ethnicity) of the patients were compared with the 
presence of conventional cardiac risk factors. Sequential patients were sampled once the 
number of euthyroid patients was identified. Likewise, the selection of specific patients with 
thyroid dysfunction continued until a sufficient sample size for predetermined statistical 
analysis was obtained. Participants were over 18 years of age and had the following 
documented during admission:  
 Thyroid stimulating hormone (TSH) 
 Free T4 (FT4)  
 Lipid profile 
 Random blood glucose level  
 Electrocardiogram (ECG)  
 Cardiac enzymes 
Inclusion criteria 
The inclusion criteria were based on the following: 
 Males and females 
 Patients who were of Black, White and Indian origin   
 Patients who were 18 years and above.  
 Patients who were diagnosed with acute coronary syndrome  
 Patients with thyroid function result between January 2010 and December 2018 
Exclusion criteria 
The following were excluded from the study:  
 Severely ill patients who have clinical evidence of sepsis or with concomitant 
presence of any predominant severe systemic disease 
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 In-Hospital death prior to blood draws 
Data collection technique 
The instrument used for collecting data was a data collection sheet. The demographic and 
clinical information about the population sample for the study were accessed from a hard 
copy database and entered into a data collection sheet. The researcher made sure that the 
confidentiality of patients’ data was ensured. This information was filled on an excel 
spreadsheet which was used to analyze the data using SPSS 25 version 24 with the help of a 
statistician.  
Data analysis 
Data were processed using IBM SPSS (IBM Corp. Released 2016. IBM SPSS Statistics for 
Windows, Version 24.0. Armonk, NY: IBM Corp.). An abnormal thyroid state was defined 
as hypothyroidism a TSH greater than 5.50mIU/L with an FT4 less than 11.5pmol/L or 
hyperthyroid state as a TSH less than 0.35Miu/l and an FT4 greater than 22.7pmol/L. 
Conventional cardiovascular risk factors that were used in multivariate analysis included the 
patients’ age, total cholesterol, triglyceride, HDL, pulse rate, and blood pressure. The area of 
infarcted tissue was also compared to the patients’ thyroid function.  
 The following were considered during data analysis: 
 Fisher’s exact and chi-square were used to test the significant difference between 
acute coronary syndrome outcomes and thyroid dysfunction 
 To determine the risk of having a thyroid abnormality for each race, a multinomial 
regression was conducted showing the relative risk for each variable by thyroid type 
using euthyroid patients as the referent group.  
 Multinomial logistic regression was done to identify risk factors due to the thyroid 
state. The model included single variables as independent variables to identify the 






Creswell (53) posits that the researcher must respect the rights, needs, values, and desires of 
the participants. Ethical approval was obtained from the University of KwaZulu-Natal 
(UKZN) Biomedical Research and Ethics Council (BREC) Ethics Committee (BE 454/17). 
Permission to conduct the research was granted by Addington Hospital. The anonymity of 
patients included was maintained and there was no specific mention of any patient’s 
personal information (such as names, birth dates identification number and hospital 
number). The study was completely retrospective and non-interventional. All the records 
will be safeguarded to ensure no one has access to it and will be deleted by the researcher 
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Abstract 
Background: Thyroid dysfunction is a major risk factor for  increasing acute coronary syndrome and mortality 
It is possible that this association is through the modification of conventional risk factors for ischaemic heart 
disease. The aim of our study was to examine the association and outcome among patients with hyperthyroidism, 
hypothyroidism and thyroid function who were presented with an acute coronary syndrome (ACS). 
Methods: A cross-sectional study was utilised which included 79 patients admitted between January 2010- 
September 2018 with acute Myocardial infarction. The patients were divided into three groups: 
Group 1: included 27 hypothyroid patients, Group 2: included 27 euthyroid patients and Group 3: 25 
hyperthyroid patients. The patients were compared with age, gender and ethnicity and the presence of 
conventional cardiac risk factors. 
Result: Black patients were significantly more likely be hypothyroid when presenting with myocardial 
infarction, there was no significant correlation between thyroid function and conventional risk factors in all 
other groups studied. 
Conclusion: There was no significant difference between conventional risk factors with both hypothyroid and 





Subclinical hypothyroidism and hyperthyroidism have been associated with an increased risk 
of acute coronary syndrome and mortality. Factors contributing to this association include; a 
high concentration of total cholesterol (1,2,3,4) and increase risk of atherosclerosis, (5,6) and 
altered cardiovascular hemodynamics. (7,8,9,10,11,12). Studies have shown that overt 
hypothyroidism is strongly associated with all components of coronary artery disease (CAD) 
but the relationship between subclinical hypothyroidism and CAD has not been 
ascertained.(13) Hypothyroid patients may have an increased concentration of creatinine 
kinase (CK) mostly due to an increase in CK-MM which may also lead to high level of CK-
MB. This may cause confusion in the evaluation and diagnosis of myocardial injury in a 
hypothyroid patient presenting with chest pain. 
 
The Troponin I is a superior indicator to diagnose myocardial injury, but case reports of 
hypothyroid patients with increased Troponin I suggest that hypothyroidism might be a risk 
factor for myocardial injury and increase risk of cardiac death.(14,15,16,17,18) 
Hypothyroidism might also lead to hypercoagulability, endothelial dysfunction, 
hyperhomocysteinemia, impaired fibrinolysis, systemic inflammation and platelet 
abnormalities, all risk factors for CAD.(19) Changes in thyroid hormone values in the plasma 
are linked to a higher mortality in patients with acute myocardial infarction suggesting a role 
for thyroid hormone signalling in the post-ischemic cardiac recovery. This hypothesis was 
done in experimental models of ischemia-reperfusion and myocardial infarction in animals 
and accumulating evidence reveals that thyroid hormones are critical for the response of the 
myocardium to ischemic stress and that thyroid hormones may have cytoprotective properties 
that are not evident in healthy tissue and appear only during stress. This hypothesis was 
developed in 2011 on 67 patients, 12 of those patients had altered thyroid hormone values. 
(20,21) 
 
During experimental coronary artery ligation in an animal model of acute myocardial 
infarction, heart failure was found to be associated with the reduction of thyroid hormone 
receptor expression in the myocardium, leading to tissue hypothyroidism.(22) Thyroid 
hormone administration improved cardiac contractility, augmented myocardial remodelling 
and improved left ventricular function. Thyroid hormones also regulate angiogenesis, cardio-
protection, cardiac metabolism, and myocyte regeneration at molecular level; changes that 
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can reverse left ventricular remodelling by improving myocyte shape and geometry of left 
ventricular cavity, then improving recovery from acute myocardial infarction.(22)  
Acute myocardial infarctions represent a major public health problem despite improvements 
in reperfusion therapy. The 2020 World Health Organization (WHO) projections view the 
high incidence of post-ischemic heart failure as the most important cause of morbidity and 
mortality. Therefore, thyroid hormones are increasingly being recognized as significant 
players in the pathogenesis, the recovery and repair period of acute myocardial infarction.(23) 
Studies showed that subclinical hypothyroidism and hyperthyroidism presented an increase in 
the point estimates for coronary heart disease and mortality.(24) 
The aim of this study was to retrospectively look at patients presenting with a myocardial 
infarction (MI) and the following were the objectives of the study: 
 To determine if there was a difference between the demographic status (age, gender 
and ethnicity) of patients presenting with normal and abnormal thyroid function tests 
 To determine if the inpatient’s mortality and morbidity as measured by clinical 
improvement and not of the patient’s’ condition on discharge differ according to the 
patient’s thyroid status. 
 To calculate if there was an association between the thyroid state and conventional 
cardiovascular risk factors such as: age, blood pressure, lipids (total cholesterol), 
measured blood glucose and patients' pulse rate. 
 To determine if thyroid status was related to the area of infarct stratified by race and 
gender. 
Mortality was to be noted for in-patient stay and a file review at one-month post discharge 
when the patient attended for routine follow up. Patients who died prior to blood tests were 
excluded from the study.  
 
Methodology 
A cross-sectional study design was applied utilising a convenience sample of 79 patients with 
acute coronary syndrome (ACS) and thyroid dysfunction who were admitted during the 
period of January 2010 to September 2018. The three categories (hyperthyroidism, 
hypothyroidism and normal euthyroid) were investigated in association with acute coronary 
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syndrome. Demographic status (Age, gender and ethnicity) of the patients were compared 
with the presence of conventional cardiac risk factors. Sequential patients were sampled once 
the number of euthyroid patients was identified. Likewise, the selection of specific patients 
with thyroid dysfunction continued until a sufficient sample size for predetermined statistical 
analysis was obtained. Participants included in the sample were over 18 years of age. 
The research location was based at Addington Hospital which serves an urban population in 
central Durban. The demographic and clinical information about the population sample for 
the study was accessed from a hard copy database and was entered into the data collection 
sheet. Data were processed using IBM SPSS Version 24.0. An abnormal thyroid state was 
defined as hypothyroidism, a TSH greater than 5.50mIU/L with a FT4 less than 11.5pmol/L 
or hyperthyroid state as a TSH less than 0.35Miu/l and a FT4 greater than 22.7pmol/L. 
Conventional cardiovascular risk factors that were used in multivariate analysis included the 
patients’ age, total cholesterol, triglyceride, HDL, pulse rate and blood pressure. The area of 
infarcted tissue was also compared to the patients’ thyroid function.  
The following were considered during data analysis: 
 Fisher’s exact and chi-square were used to test the significant difference between 
Acute Coronary Syndrome outcomes and thyroid dysfunction 
 To determine the risk of having a thyroid abnormality for each race, a multinomial 
regression was conducted showing the relative risk for each variable by thyroid type 
using euthyroid patients as the referent group.  
 A multinomial logistic regression was done to identify risk factors due to the thyroid 
state. The model included single variables as independent variables to identify the 
most statistically significant variable for the multiple regression. 
 
Furthermore, ethical approval was obtained from the University of KwaZulu-Natal (UKZN) 
Biomedical Research and Ethics Council (BREC) Ethics Committee (BE 454/17). Permission 
to conduct the research was granted by Addington Hospital. Confidentiality and anonymity of 
patients were maintained and there was no specific mention of any patient’s personal 
information (such as names, birth dates, identification number and hospital number). The 





Data was collected from one regional hospital, 79 patients were included, 27(34.18%) 
patients were euthyroid, 27(34.18%) patients were hypothyroid and 25 (31.65%) patients 
were hyperthyroid, the demographics of the study participants showed 58 (73.42%) were 
Indian, 9 (11.39%) were black and 12 (15.19%) were white. Gender distribution was 30 
(37.97%) were female and 49 (62.03%) were male.  
 
 
Table 1: Gender and thyroid function of study participants 
 
Our study cohort comprised 29 men with abnormal thyroid function, 23 women with 
abnormal thyroid function, 20 men who were euthyroid and 7 women were euthyroid. The 
table indicates that 59 % of men had abnormal thyroid function versus 77% of women 
(p=0.08). Men were more likely to have hypothyroidism and women hyperthyroidism but 
these differences were not statistically significant (p= 0.1868).  
 Gender P-value Race P-value 
Thyroid type Female Male  Indian Black Whit
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Black patients were most likely to have thyroid dysfunction if they were presented with MI 
(100%) compared to white patients who were least likely to have concomitant thyroid disease 
(58%). Black patients were significantly more likely to be hypothyroid than either white or 
Indian patients (p=0.019). 
We found nine Black patients with abnormal thyroid function, seven white patients with 
abnormal thyroid function. Zero Black patients with normal thyroid function and five white 
patients with normal thyroid function. There was a significant difference between the two 
ethnic groups, p-value = 0.039. Risk ratio = 1.71 with p-value = 0.0265. 
 







 Gender Race 
ACS Female Male Indian Black White 
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ACS Female Male Indian Black White 

































































Table 5: ACS by Thyroids 
 Thyroid (n = 79) p-
value 
ACS Hyperthyroid Hypothyroid Euthyroid  
1 Anterior 7 (28.00%) 8 (29.63%) 7 (25.93%) 1.000 
2 Inferior 13 (52.00%) 12 (44.44%) 14 (51.85%) 0.957 
3 Anterolateral 2 (8.00%) 3 (11.11%) 2 (7.41%) 1.000 
4 Antero-septal  3 (12.00%) 4 (14.81%) 3 (11.11%) 1.000 
5 Antero-inferior    1 (3.70%) 1.000 
Total 25 27 27  
 
 Gender Race 
ACS Female Male Indian Black White 




















































Table 2, 3, 4 and 5 show a stratification of patients by gender, race and thyroid function to 
determine if the thyroid status was related to the area of infarct. Results show that there were 





Figure 1: Age distribution of patients presenting with Myocardial infarction 
 
The average age of the patients was 58.23 years with a standard deviation of 11.08, the 
minimum age was 33 years while the maximum was 86 years. The median age was 60 years 










Table 6: Correlation between Age groups and thyroid status 
 Age groups  







Hyperthyroid 2 4 5 10 4 25 
Hypothyroid 1 8 7 8 3 27 
Euthyroid  1 6 8 9 3 27 
 Total 4 18 20 27 10 79 
          Exact p-value = 0.957 
Table 6 indicates that when interquartile ranges in patients presenting with Myocardial 
infarction were studied there was no difference in the age at presentation and patients' thyroid 
status. 
Table 7: Correlation between total Cholesterol and thyroid status 
Cholesterol Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 14 20 22 56 
% 25 35.71 39.29 100 
Normal 11 7 5 23 
% 47.83 30.43 21.74 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 
Fisher's exact =                 0.423 0.148   
 
There were 23 (29.11%) participants with recommended total cholesterol level of< 4 mmol/l 
and 56 (70.89%) with above a recommended value of > 4 mmol/l. There was no correlation 
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between total Cholesterol and thyroid status. HDL was above the recommended value of > 
1.2 mmol/l in 13 women and above the recommended value of > 1 mmol/l in 27 men.  
 
Figure 2: Cholesterol distribution of patients 
 
 










Table 8: Correlation of LDL Cholesterol with thyroid status 
 LDL 
Thyroid Coef p-value 95% CI 
Hyperthyroid -0.034 0.70 -0.21 – 1.40 
Hypothyroid -0.036 0.68 -0.21 – 0.13 
 










Figure 5: LDL distribution by thyroid 
 
 






Normal LDL in non-diabetic (less than 2.5mm/l) and in diabetic (less than 1.8mmol/l) 
 
LDL DM abnormal DM normal Total 
Normal 9 10 19 
Abnormal 34 26 60 





































Table 11 shows Triglyceride level of < 1.7mmol/l was found in 48 (61%) participants of 
which 17 were women (35.42) and 31 were men (64.58%). There was no correlation between 
Triglyceride and thyroid status. 
 HDL 
Thyroid Coef p-value 95% CI 
Hyperthyroid -0.06 0.79 -0.489- 0.371 
Hypothyroid -0.01 0.97 -0.429- 0.413 
Trig Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 7 14 10 31 
% 22.58 45.16 32.26 100 
Normal 18 13 17 48 
% 37.5 27.08 35.42 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 













Table 12: Correlation between pulse and thyroid status 
Pulse Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 15 14 13 42 
% 35.71 33.33 30.95 100 
Normal 10 13 14 37 
% 27.03 35.14 37.84 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 
 Fisher's exact =                  0.664   
 
Table 12 shows that pulse which is the measure of heart beats per minute was in the normal 
range (60 – 99 beats/minute) among 71 (89.87%) participants, 27 (38.03%) women and 44 
(61.97%) men. There was no correlation between pulse rate and thyroid status. 
 
 
Table 13: Correlation between systolic blood pressure and thyroid status 
SBP Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 12 12 13 37 
% 32.43 32.43 35.14 100 
Normal 13 15 14 42 
% 30.95 35.71 33.33 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 




There were 51 participants with normal SBP (100 -139 mmHg), 18 (35.29%) women and 33 
men (64.71%) while normal diastolic pressure (70-89mmHg) was found in 54 participants, 21 
women (38.89%) and 33 men (61.11%). There was no correlation between systolic blood 
pressure and thyroid status. 
 
Table 14: Correlation between Diastolic blood pressure and thyroid status 
DBP Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 13 11 10 34 
% 38.24 32.35 29.41 100 
Normal 12 16 17 45 
% 26.67 35.56 37.78 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 
 Fisher's exact =                 0.603   
 















Table 15: Correlation between Serum random glucose and thyroid status 
Glucose  Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 12 8 11 31 
% 38.71 25.81 35.48 100 
Normal 13 19 16 48 
% 27.08 39.58 33.33 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 
 Fisher's exact =                 0.423   
 
Table 15 indicates that Serum random Glucose was less 7mmol/l among 53 participants of 
which 17 (32.08%) were men and 36 (67.92%) were women. There was no correlation 
between Serum random Glucose and thyroid status. 
 
 





Table 16: Correlation between CPK and thyroid status 
CPK Hyperthyroid Hypothyroid Euthyroid Total 
Abnormal 11 21 10 42 
% 26.19 50 23.81 100 
Normal 14 6 17 37 
% 37.84 16.22 45.95 100 
Total 25 27 27 79 
 31.65 34.18 34.18 100 
 Fisher's exact =                  0.006   
 
Creatine phosphokinase (CPK) with range (20 – 180) was normal among 37 (46.84%) 
participants, 14 (37.84%) women and 23 (62.16%) men. There was a significant difference 
between CPK and thyroid status. Hypothyroid patients were significantly more likely to have 
high CPK than Euthyroid or Hyperthyroid patients. 
 
 




Table 17: Baseline continuous variables of the study cohort 
Variables Mean (SD) Median (IQR) Min Max 
Cholesterol (mmol/l) 4.80  
(1.24) 
4.87  
(3.89 – 5.73) 
2.22 7.27 
HDL (mmol/l) 1.19  
(0.44) 
1.13  
(0.94 – 1.31) 
0.50 3.99 
Triglyceride (mmol/l) 1.82  
(1.38) 
1.41  
(0.96 – 2.23) 
0.49 7.67 
Glucose 7.66  
(3.73) 
6.7  
(5.7 – 8.1) 
3.8 32.6 





(113 – 148) 
56 183 





(69 – 90) 
30 110 
Pulse (beat/min) 84.09  
(14.98) 
85  
(72 – 95) 
58 130 
CPK (U/L) 392.77  
(614.08) 
185  
(101 – 351) 
44 3938 
TSH  (mlU/L) 5.63  
(19.13) 
1.43  
(0.32 – 3.04) 
0.01 149.36 
FT4 (pmol/l) 13.84  
(4.24) 
13.1  
(11.3 – 15.3) 
2.20 26.30 
LDL (mmol/l) 2.90  
(1.03) 
2.9  











Table 18: Categorical variables 
Variables Male - n (%) Female - n (%) 

















































ECG (n = 79) 
Anterior = 1 
Inferior = 2 
Anterolateral = 3 
Antero-septal = 4 













ECHO (n = 79)  
No RMWA = 0 











30 participants (38%) had a normal range Ejection Fraction (54% - 66%) for their ECHO, of 
these 21 (70%) had RMWA and 9 (30%) had No RMWA. Of these 21, there were 10 women 
but only five with the cut-off age of 65 years and above, while 11 men fitted the criteria, 
however only five men had the cut-off age of 55 years and above. 
 
To determine the risk of having a thyroid abnormality for each race, a multinomial regression 
was conducted showing the relative risk for each variable by thyroid type using euthyroid as 
the reference group. The result below shows the relative risk ratio (RRR) for Indians for each 
risk factor. This model was developed in a stepwise fashion, that is, by adding one variable at 
a time and adjusting the model. In some cases, a poor estimate was produced whereby 
standard errors and RRR were too large because a convergence could not be achieved. This 
means the categories had too small numbers for each thyroid state. This was more 
pronounced in the white and black ethnic groups with 12 and 9 observations respectively. For 
instance, in the black ethnic groups, euthyroid could not be used as a base outcome, as there 
were no observations for most of the risk factors, thus hyperthyroidism was used. It is 
important to note, none of the variables were statistically significant. 
  
 
Table 19: Relative risk for Indians 




Hyperthyroid       
Chol 0.7427 0.2649 -0.83 0.404 0.3691 1.4943 
Sex 0.3772 0.3455 -1.06 0.287 0.0627 2.2709 
DM 1.9299 1.9908 0.64 0.524 0.2555 14.5748 
SBP 0.9663 0.0246 -1.35 0.177 0.9192 1.0157 
DBP 1.0524 0.0402 1.34 0.181 0.9766 1.1342 
Hypt 0.4661 0.4173 -0.85 0.394 0.0806 2.6948 
Smoking 0.4707 0.412 -0.86 0.389 0.0847 2.6168 
FHDM 3.5719 4.1905 1.09 0.278 0.3583 35.6044 
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FHHypt 0.5522 0.5679 -0.58 0.564 0.0736 4.145 
ECG 0.9085 0.3464 -0.25 0.801 0.4303 1.9183 
Age 1.0034 0.0467 0.07 0.942 0.916 1.0991 
_cons 9.9348 40.6041 0.56 0.574 0.0033 29928.33 
       
Hypothyroid       
Chol 1.1782 0.4408 0.44 0.661 0.5659 2.4529 
Sex 0.8111 0.767 -0.22 0.825 0.1271 5.1765 
DM 2.6994 2.8418 0.94 0.346 0.3429 21.2517 
SBP 0.9764 0.0271 -0.86 0.389 0.9248 1.0309 
DBP 1.0513 0.0422 1.25 0.212 0.9718 1.1373 
Hypt 2.9189 2.8545 1.1 0.273 0.4294 19.8439 
Smoking 0.4584 0.4178 -0.86 0.392 0.0768 2.7354 
FHDM 0.5548 0.6957 -0.47 0.638 0.0475 6.4792 
FHHypt 0.6256 0.7393 -0.4 0.691 0.0617 6.3418 
ECG 0.5698 0.244 -1.31 0.189 0.2461 1.3189 
Age 0.9995 0.0551 -0.01 0.992 0.8972 1.1134 
_cons 0.4507 2.2939 -0.16 0.876 0 9681.374 
Euthyroid Base 
outcome 
     
The result from table 16 shows that if you are Indian and Hyperthyroid, you were more likely 
to have lower cholesterol than if you were Euthyroid. RRR = 0.74. Similarly, if you are 
Indian and Hyperthyroid, you were more likely to have a higher blood pressure than if you 
were Euthyroid. RRR=0.4661. Hypothyroid Indians are more likely to have lower cholesterol 
than if they were Euthyroid. RRR =1.1782.  If you were Indian and Hypothyroidism, you 









Table 20: Relative risk for White patients 




Age 1.1983 0.1350 1.61 0.108 0.9610 1.4944 
Chol 0.0903 0.1350 -1.61 0.108 0.0005 1.6891 
       
Hypothyroid       
Age 1.0130 0.0551 0.24 0.812 0.9105  1.1270  
Chol 0.8609 0.4958 -0.26 0.795 0.2780 2.6616 
Euthyroid Base 
outcome 
     
 
The result indicates that if you are white, conventional risk factors of age and total cholesterol 














 Table 21: Relative risk for Blacks 
  
Black males were more likely to have hypothyroidism than to be Euthyroid if they presented 
with Myocardial Infarction. Black females were also more likely to have hypothyroidism 
than to be Euthyroidism if they presented with Myocardial Infarction. 
 
 










Thyroid RRR Std 
err 






Hypothyroid       
Sex 0.2566 0.5082 -
0.69 
0.492 0.0053 12.449  
Chol 1.3058  0.9131 0.38 0.703 0.3317 5.1411  
FT4 1.0726 0.2908  0.26 0.796 0.6304  1.8248 
Hyperthyroid (base 
outcome) 
     
 SBP 
Thyroid Coef p-value 95% CI 
Hyperthyroid -<0.001 0.63 -0.005 – 0.003 



























Thyroid Coef p-value 95% CI 
Hyperthyroid -0.001 0.75 -0.008 – 0.006 
Hypothyroid -<0.001 0.89 -0.006 – 0.007 
 Race 
Thyroid Coef p-value 95% CI 
Hyperthyroid -0.19 0.47 -0.32 – 0.70 





Table 25: Correlation of Sex with thyroid status 
 Sex 
Thyroid Coef p-value 95% CI 
Hyperthyroid -0.69 0.17 -1.69 – 0.30 
Hypothyroid -0.66 0.18 -1.61 – 0.29 
     
 















Thyroid Coef p-value 95% CI 
Hyperthyroid -0.19 0.59 -0.90 – 0.51 



























Thyroid Coef p-value 95% CI 
Hyperthyroid -0.44 0.42 -0.62 – 1.49 
Hypothyroid -0.41 0.52 -1.65 – 0.83 
 DM 
Thyroid Coef p-value 95% CI 
Hyperthyroid -0.33 0.61 -1.59 – 0.93 
Hypothyroid 0.28 0.69 -1.10 – 1.67 
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Table 29: Correlation of Age with thyroid status 
 Age 
Thyroid Coef p-value 95% CI 
Hyperthyroid 0.01 0.43 -0.01 – 0.18 
Hypothyroid 0.00 0.98 -0.01 – 0.01 
 
 
Table 30: Correlation of smoking with thyroid status 
 Smoking 
Thyroid Coef p-value 95% CI 
Hyperthyroid -0.73 0.17 -1.77 – 0.32 
Hypothyroid -0.07 0.89 -1.10 – 0.95 
 
Table 31: Correlation of FHHypt with thyroid status 
 FHHypt 
Thyroid Coef p-value 95% CI 
Hyperthyroid 0.30  0.51 -0.60 – 1.18 








Figure 12: Race distribution of patients presenting with Myocardial infarction 
 
Patient outcome: 
There was no in-hospital mortality during the admission for the index of an acute coronary 
syndrome. Thirty-day mortality 1/79 (1.3%), inpatient with hypothyroidism. 
 
Discussion 
The principal finding of our study is that there was no significant correlation between thyroid 
function and Myocardial infarction in all groups studied except for those with black ethnicity. 
Black patients in our study were more likely to be hypothyroid when presented with 
myocardial infarction. There was no significant difference between gender and thyroid status 
or the area of infarcted tissue. More so, there was no significant difference between 
conventional risk factors: total cholesterol, calculated LDL cholesterol, HDL cholesterol, 
triglyceride, random plasma glucose, pulse, systolic blood pressure and diastolic blood 
pressure with both hypothyroid and hyperthyroid patients with myocardial infarction in our 
study. Therefore, our findings differ from previous studies that showed elevation of 
cholesterol and heart rate which was more in females than in males.  
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Furthermore, there was a significant correlation between thyroid status and creatinine 
phosphokinase, hypothyroid patients were significantly more likely to high CPK than 
euthyroid or Hyperthyroid patients. Because our patients had wall motion abnormalities and 
ECG changes consistent with acute coronary syndrome, it is unlikely that our patients were 
incorrectly diagnosed with myocardial infarction. Due to resource limitations, unfortunately, 
FT3 was not measured although many previous studies showed a highly inverse correlation 
exists between coronary heart disease and thyroid hormone which was extended across a 
wide spectrum of value of fT3. 
In addition, no previous studies comparing ethnicity in myocardial infarction and thyroid 
dysfunction are described in the literature. Our study showed that Black patients were most 
likely to have thyroid dysfunction if they are presented with a MI (100%) compared to white 
patients who were least likely to have concomitant thyroid disease (58%). Black patients 
were significantly more likely to be hypothyroid than either white or Indian patients 
(p=0.019). 
Mortality in our cohort was low and due to small numbers, no comparison with thyroid status 
could be made. This finding is different from other studies where it was found that there was 
an association between Hypothyroidism and decreased survival in Myocardial infarcted 
patients with statistical significance (RRs of 1.18 to 1.55) (24). 
 
Study limitations and advantages 
The limitation of this study was that it was a single-centre study. Small numbers of patients in 
each ethnic group other than Indian made statistical analysis challenging, furthermore this 
was a retrospective review, so all clinical data relied on record keeping.  
Study advantages: this is the first published data of thyroid dysfunction cross different 
ethnic groups in South Africa. 
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Appendix 1: The final Study Protocol (Include the final protocol which was given full 
approval by Brec and/or the postgrad office) 
 
Re-amended Research protocol: MMED (Internal Medicine) 
Student: Dr. Mustafa Ben Hkouma 
Student number: 214585722 
Supervisor: Dr. Susan L Brown  
______________________________________________ 
Title of study: 




Aim of study: 
To examine the association and outcome between patients with hyperthyroidism ,  







 . To describe the demographic profile of patients presenting with thyroid dysfunction and 
Acute Coronary Syndrome and compare them with euthyroid patients. 
. To compare the prevalence of hyper – and hypothyroidism in patients with Acute Coronary 
Syndrome. 
 . To compare the clinical outcomes of thyroid dysfunction and acute coronary syndrome.  




. To calculate  if there is  a difference in the age , gender and ethnicity between patients 
presenting with normal and abnormal thyroid function tests. 
. To determine the prevalence of thyroid dysfunction in patients presenting with thyroid 
dysfunction 
. To determine if the inpatient mortality  and morbidity as measured by clinical improvement 
or not of the patient’s condition on discharge. 
. To calculate if there is an association between the thyroid state and conventional 
cardiovascular risk factors; age , Blood pressure , lipids, glucose status and the patient’s 
eventual outcome. 
 
Background and literature: 
 Subclinical hypothyroidism and subclinical hyperthyroidism have  been  associated with an 
increased risk of acute coronary syndromes and mortality. Factors contributing to this 
association include; an increase concentration of cholesterol (1, 2,17,18) and increase risk of 
atherosclerosis, (3, 4) and altered  cardiovascular hemodynamics. (5, 6, 7, 8, 9 and 10). 
 Hypothyroid patients may have an increased concentration of creatinine kinase mostly due to 
increase CK-MM which also lead to increase level of CK-MB. This may confuse doctors 
during their evaluation and diagnosis of myocardial injury in a hypothyroid patient presenting 
with chest pain. 
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 The Troponin I is a superior marker to diagnose myocardial injury, but  cases reports of 
hypothyroid patients  with an increased Troponin I , suggest that  hypothyroidism might be a 
risk factor for myocardial injury and increase risk of cardiac death (11, 12, 13, 14and 15). 
 Clinical and experimental data have suggested a potential negative effect of low T3 on the 
prognosis of cardiac disease and increase mortality rate (16). 
Low T3 concentrations are a strong independent predictive marker for poor prognosis in 
cardiac patient based on study was done in 2002 on 573 patients ( 173 patients with low T3  
and 400 patients with normal T3 (12). 
The  reduction of ft3  level in patients with CAD  is a marker of disease rather than an 
element contributing directly to disease prognosis. However, because ft3 represents the 
biologically active form of thyroid hormone, then as isolated reduction in ft3 levels could 
constitute a model of abnormal thyroid hormone metabolism acting as a risk factor for CAD 
in a similar fashion to overt or subclinical hypothyroidism. For example  the prevalence of 
dyslipidemia and arterial hypertension, is greater in patients affected by hypothyroidism (19). 
Hypothyroidism might also lead to hypercoagulability, endothelial dysfunction, 
hyperhomocysteinemia, impaired fibrinolysis, systemic inflammation and platelet 
abnormalities (19). 
The changes in thyroid hormone in the plasma are linked to high mortality in patients with 
acute myocardial infarction, indicating strong implication of thyroid hormone signaling in the 
post-ischemic cardiac recovery , this hypothesis was done in experimental models of 
ischemia- reperfusion and myocardial infarction in animals and accumulating evidence 
reveals that thyroid hormone is critical for the response of the myocardium to ischemic stress 
and thyroid hormone may have cytoprotective properties that are (( silent)) in healthy tissue 
appear only during stress. This hypothesis was done in 2011 on 67 patients with 12 patients 
have thyroid hormone changes (20). 
During experimental coronary artery ligation in an animal model of acute myocardial 
infarction, heart failure found to be associated with reduction of thyroid hormone receptor 
expression in the myocardium, leading to tissue hypothyroidism.The thyroid hormone 
administration improves cardiac contractility, augments myocardial remodeling and improve 
left ventricular function. Also regulate angiogenesis, cardio-protection, cardiac metabolism, 
and myocyte regeneration at molecular level, changes that can reverse left ventricular 
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remodeling by improving myocyte shape and geometry of left ventricular cavity, then 
improving recovery from acute myocardial infarction (21).  
Acute myocardial infarction represent a major public health problem. Despite improvements 
in reperfusion therapy, the 2020 World Health Organization projections view the high 
incidence of post-ischemic heart failure as the most important cause of morbidity and 
mortality. In this regard, thyroid hormones are increasingly being recognized as significant 




Addington Hospital, KwaZulu-Natal, Republic of South Africa. 
 
Study population: 
The study population is selected patients admitted to Addington  Hospital with Acute 
Coronary Syndrome.  
Study sample: 
The study sample is randomly selected patients with Acute Coronary Syndrome and thyroid 
dysfunction admitted during the period January 2010 to September 2018. 
Sample size: 79 
 
Sampling technique: 
The parameter will be used to calculate sample size: 
1. Statistical test: Chi square test 
2. Effect size: 0.40 
3. Type one error (α): 0.05 ( 5%)  ( recommended in literature of medical study)   
4. Type tow error ( β) : 0.2 ( 20%)  (recommended in literature of medical study) 




Output parameter:   
1. non centrality parameter (  ƛ ) : 12.96. 
2. critical chi square= 11.07 
3. Total sample size =79 
4. Actual statistical power= 0.8 ( 80% ).  
 
The three categories  ( hyperthyroidism, hypothyroidism and normal thyroid  function) will 
be investigated in association with Acute Coronary Syndrome. 
Therefore means that the total number of 79 participants will be divided by three  to give a 
minimum number of individuals from each thyroid function  category to be included in the 
study ie.  79/3= 27/27/25. 
Therefore means that a minimum of 25 patients of Hyperthyroidism, 27 patients of 
Hypothyroidism and 27 patients of normal thyroid  function will be included in the study. In 
the situation where they are more than 27 individual in the category,  a simple random 




All participant in study must have: 
 Age of 18 and more 
 Diagnosis of acute coronary syndrome with ECG changes and positive cardiac 
enzymes 
 Patients with thyroid function results 
Exclusion criteria:. 
 severly ill patients, that is, with clinical evidence of sepsis or with concomitant 
presence of any predominant sever systemic disease. 
 





Study design: retrospective cross-section analytic study. 
All participants in the study will have the following documented during admission: 
        . Admission diagnosis 
The following investigations will be done in all the participant who meet the inclusion criteria 
as part of their standard care: 
 . Thyroid function test (TSH, FT4).  
. Lipid profile 
. Blood glucose level 
. ECG 
. Cardiac enzymes. 
 
Study period: 
January 2010 to September 2018. 
 
Data collection Technique: 
Data will be accessed from a hard copy database and will be entered onto a data collection 
sheet. The patient records although are retrospectively analyzed, Confidentiality of patient 
data will be ensured. 
 
Limitation of the study: 
Due to retrospective nature of the study, incomplete data and poor follow up may decrease 











The anonymity of patients included in the study will be maintained. There will be no specific 
mention of any personal patient information in the study. The study is completely 
retrospective and non-interventional. 
 
Data analysis techniques: 
Data will be processed using the following statistical tools, SAS (SAS Institute Inc. 2016. 
Base SAS® 9.4 Procedures Guide. Cary, NC: SAS Institute Inc), IBM SPSS (IBM Corp. 
Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.). 
Continues variables will be summarized using mean and standard deviation. Skewed (non- 
normal) data will be summarized using median and tertiles. Differences in means between 
continues variable will be analyze using Student’s t-test. However, if data is not normal 
Wilcoxon test will be used. Association between Acute Coronary Syndrome outcomes and 
thyroid dysfunction will be analyze using Pearson’s Chi squared test, or fisher’s exact where 
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ID CODE Race Sex Age Chol Trig HDL MI
1 1 Indian M 51 6.49 7.67 0.8 X
2 1 Indian F 63 3.45 1.15 1.22 X
3 1 Indian M 70 4.6 1.02 0.94 X
4 1 Indian M 38 2.97 1.31 1.03 X
5 1 White F 86 5.31 0.93 1.79 X
6 1 Indian F 66 2.26 1.93 1.2 X
7 1 Indian F 64 2.22 0.73 1.2 X
8 1 Black M 43 5.19 1.71 0.99 X
9 1 Indian M 60 4.9 0.74 0.66 X
10 1 Indian M 49 6.37 0.67 1.56 X
11 1 Indian F 63 3.88 0.62 1.6 X
12 1 Indian F 66 5.06 0.78 1.98 X
13 1 Black M 47 5.2 1.15 1.31 X
14 1 Indian F 75 3.4 1.31 0.77 /
15 1 White M 33 2.3 1 0.67 X
16 1 Indian M 66 5.2 2.09 0.87 X
17 1 Indian M 64 3.5 0.95 0.89 X
18 1 Indian F 69 3.6 0.59 1.2 X
19 1 Indian M 58 3.4 0.64 1.93 X
20 1 Indian F 43 5.31 1.46 1.09 X
21 1 Indian M 71 3.9 1.02 0.93 X
22 1 Indian F 61 4.51 1.85 0.98 X
23 1 White F 73 5.45 2.23 1.9 /
24 1 Indian F 58 4.9 1.94 0.95 /
25 1 Indian M 54 5.74 1.43 1.26 X
26 2 Black M 60 6.65 2.26 0.9 X
27 2 Indian M 44 6.59 4.33 1.33 X
28 2 Indian M 65 4.7 0.96 1.07 X
29 2 White M 66 5.8 2.11 1.19 X
30 2 White M 62 5.29 0.84 1.21 X
31 2 Indian M 50 5.86 2.93 0.89 X
32 2 Indian M 52 6.21 4.63 0.72 X
33 2 Black M 42 3.04 0.89 0.95 X
34 2 Black F 35 5.2 1.09 1.13 X
35 2 White F 69 7.27 4.96 1.11 /
36 2 Indian F 71 3.69 1.06 1.11 /
37 2 Indian M 61 4.21 1.62 1.42 X
38 2 Black M 44 3.33 0.5 1.51 X
39 2 Indian M 51 5.1 5.25 0.6 /
40 2 White F 69 6.36 2.65 1.01 X
41 2 Indian F 52 6.76 4.28 1.18 X
42 2 Indian F 56 3.12 1.05 0.94 X
43 2 Indian F 78 5.14 1.46 1.6 X
44 2 Indian M 50 4.26 2.38 0.9 X
45 2 Indian F 56 4.61 0.97 1.5 /
46 2 Indian M 69 4.25 1.7 0.8 X
47 2 Indian F 71 5.73 7.4 0.5 X
48 2 Indian M 43 7.06 0.65 3.99 X
49 2 Black F 45 2.24 0.49 1.16 X
50 2 Black M 46 4.87 2.22 0.91 X
51 2 Black F 60 3.83 2.35 1.06 /
52 2 Indian M 64 2.67 0.57 1.15 /
53 3 Indian M 76 4.37 1.21 1.27 X
54 3 Indian M 77 4.14 1.33 0.73 /
55 3 Indian F 64 4.24 1.85 1.6 X
56 3 Indian M 68 6.14 1.63 1.07 X
57 3 Indian M 52 5.69 1.04 0.97 /
58 3 Indian M 36 5.95 2.49 1.28 X
59 3 Indian M 62 5.05 2.61 0.82 X
60 3 Indian F 66 6.79 1.33 1.11 X
61 3 Indian F 56 6.81 2.14 1.28 X
62 3 Indian M 59 4.82 0.86 0.9 /
63 3 Indian F 61 6.29 2.49 1.18 X
64 3 Indian F 50 4.44 1.4 1.32 X
65 3 Indian M 59 3.89 0.77 1.19 /
66 3 Indian M 50 3.7 0.93 1.41 X
67 3 Indian M 51 4.59 1.3 1.4 /
68 3 White M 50 5.99 3.25 1.53 X
69 3 Indian M 69 3.92 0.78 1.45 X
70 3 White F 64 5.23 1.46 1.06 X
71 3 Indian M 60 4.22 1.41 1.58 X
72 3 White M 53 4.87 2.75 0.9 X
73 3 White M 44 6.45 2.78 1.24 X
74 3 Indian F 66 5.28 2.28 1.05 X
75 3 Indian M 52 3.97 1.18 1.31 /
76 3 Indian M 64 3.55 0.99 1.2 X
77 3 Indian M 48 5.56 1.7 1.11 X
78 3 Indian M 50 5.69 1.64 1.25 X
79 3 White M 71 4.58 1.44 0.98 X
Hypt DM Smoking CAD FH Hypt FH DM Pulse SBP DBP
/ / / / / / 100 124 81
/ / X / / / 80 113 69
/ X X / X / 80 150 90
X X X / X / 110 91 57
/ / X / / / 90 145 91
X / X / / / 80 115 76
/ / X / / / 120 142 97
/ X / X X / 65 145 90
X X / / X / 68 109 80
X X / / X X 90 108 67
/ X X X X X 60 76 50
/ / X / X / 115 170 90
X X X X X X 92 102 69
/ / X / / / 95 157 57
X X X X X X 90 109 69
X X / X X X 82 142 96
X / / X X / 70 143 83
/ / X X / / 96 128 71
/ / / / / / 75 155 95
/ X / / / / 85 130 90
X / / / / / 90 56 30
X / / / / / 70 115 72
/ X / / / / 72 111 72
/ / X / / / 85 129 90
X X X / / / 88 130 88
/ X / X X X 60 165 103
X X / X X X 110 111 84
/ / X / / / 96 138 96
/ / / X / / 110 150 90
X X / X X X 90 130 92
/ / / / X / 89 157 94
X X / X X X 72 120 69
/ X / X X X 106 116 79
X X / / X X 72 135 85
/ / / / X / 80 122 70
/ / X X / / 96 137 79
/ X / X X X 96 130 91
X X X X X X 90 118 74
/ X X X X X 58 123 75
X X X X / / 74 143 59
/ X / / / / 65 96 59
/ / / / X / 98 142 79
/ / X / / / 70 168 82
X X / / X X 73 137 84
/ / X / / / 95 151 92
/ / / / / / 71 152 82
/ / X / / / 87 107 71
/ X X X X X 91 143 98
/ / / X / / 65 133 95
X X / X X X 87 97 64
/ X X / X X 77 129 76
/ X X X X X 94 96 61
/ / X X X X 71 131 70
X X / / X X 98 120 62
/ / X / / / 97 159 86
/ / / / / / 84 125 57
/ / / / / / 70 157 72
X X / / / / 63 102 62
/ / / / / / 88 120 84
/ / / / X / 75 150 47
X X / X X X 59 125 80
/ X / / / / 94 95 61
X X X X X X 130 138 75
/ X X / / / 80 152 91
/ X / X X X 71 99 59
X X / / / / 93 89 60
/ / / / X X 71 151 91
/ / X X / / 74 127 79
X X / X X / 86 127 75
/ X X X X X 61 183 93
/ X / X X X 99 156 106
/ X / X X X 96 153 103
X / X X X X 65 115 72
/ / X / / / 82 124 84
X X / X X X 73 101 73
X / X X X / 84 110 72
X X / / / / 77 118 76
/ X / / / / 87 148 99
/ / X / / / 95 180 110
PCK T on adm Glucose TSH FT4 ECG ECHO LDL
99 13937 7.9 0.7 23.5 Ant STEMI  No RMWA EF60% 4.9
73 6041 7.5 0.25 22.4 Ant STEMI RMWA EF63% 1.7
66 > 50.000 5.7 0.31 12.8 Inf STEMI RMWA EF42% 3.2
92 46940 6.4 0.08 22.8 Antrolateral STEMI RMWA EF45% 1.3
1837 >50.000 5.6 0.21 16.2 Ant STEMI RMWA EF42% 3.1
79 6031 11 0.13 16.5 Inf STEMI No RMWA EF62% 0.4
629 11764 9.6 0.62 24.2 Antroseptal STEMIRMWA EF30% 0.9
172 14344 6 0.31 15.4 Inf STEMI RMWA EF52% 3.4
112 1089 5.8 0.27 13.9 Ant STEMI No RMWA EF62% 3.9
3938 >50.000 7.3 0.32 13.6 Ant STEMI RMWA EF38% 4.5
93 1665 6.1 0.19 12.5 Inf STEMI RMWA EF35% 2
52 10499 16.9 4.01 22.8 Antrolateral STEMI RMWA EF35% 2.7
69 24747 7.9 0.06 12.3 Ant STEMI RMWA EF35% 3.4
285 345 7.2 0.29 18.2 Antroseptal STEMIRMWA EF38% 2
258 7124 7.1 0.01 21 Inf STEMI RMWA EF50% 1.2
264 27957 6.7 0.28 14.2 Antroseptal STEMIRMWA EF43% 3.4
1216 40488 8.1 0.22 15.3 Inf STEMI No RMWA EF57% 2.2
161 42824 11.1 0.28 13.8 Inf STEMI RMWA EF57% 2.1
129 9509 7.8 0.21 13.6 Inf STEMI RMWA EF53% 1.2
63 20988 5.6 0.32 13 Inf STEMI RMWA EF52% 3.6
353 3066 6.4 0.18 23.4 Inf STEMI RMWA EF42% 2.5
351 33138 32.6 1.49 23.4 Inf STEMI RMWA EF61% 2.7
207 802 3.8 0.2 13.1 Inf STEMI RMWA EF57% 2.5
96 >50.000 13.3 2.29 26.3 Ant STEMI RMWA EF71% 3.1
222 47 4.6 0.15 12.5 Inf STEMI RMWA EF42% 3.8
370 189 5.3 2.08 11.4 Antroseptal STEMIRMWA EF57% 4.7
184 18 6.2 0.71 10.2 Ant STEMI RMWA EF42% 3.3
181 7126 7.9 24.82 11.2 Inf STEMI RMWA EF43% 3.2
619 2207 7.3 1.56 11.3 Antroseptal STEMIRMWA EF50% 3.6
2365 >50.000 8.3 0.61 10.3 Ant STEMI RMWA EF47% 3.7
158 8466 6.1 17.08 12.3 Inf STEMI RMWA EF50% 3.6
580 28245 6.1 1.72 9.5 Ant STEMI No RMWA EF57% 3.8
274 11500 6.7 0.64 10.2 Antroseptal STEMIRMWA EF36% 1.6
188 27427 6.3 1.53 10.5 Ant STEMI No RMWA EF61% 3.6
214 3165 10.2 7.02 11 Ant STEMI RMWA EF44% 4.4
212 11743 10.4 3.77 11.4 Inf STEMI RMWA EF62% 2.1
364 39368 5.2 4.13 11.3 Ant STEMI RMWA EF32% 2
606 >50.000 5 0.48 10.8 Antroseptal STEMINo R WA EF30% 1.6
159 9378 12.2 0.36 10.4 Inf STEMI RMWA EF48% 3.8
75 2856 5.7 2.26 10.5 Inf STEMI No RMWA EF63% 4.1
1310 >50.000 5.9 9.08 7.9 Inf STEMI RMWA EF50% 3.6
667 25963 14.7 2.47 9.6 Inf STEMI RMWA EF59% 1.7
185 5619 7.1 8.34 12.2 Antrolateral STEMI RMWA EF56% 2.9
2007 >50.000 6.7 2.15 10.9 Antrolateral STEMI RMWA EF45% 2.3
213 4236 6.4 75.48 7.8 Ant STEMI RMWA EF62% 2.7
323 17475 6.3 38.67 6.9 Inf STEMI RMWA EF54% 2.7
111 6721 6.6 149.36 2.2 Ant STEMI RMWA EF52% 4.2
94 5601 7 0.43 10.3 Inf STEMI RMWA EF47% 3.7
281 12911 10.7 3.59 10 Antrolateral STEMI No R WA EF64% 1
303 3527 6.7 3.32 10.2 Inf STEMI RMWA EF62% 2.9
1168 37633 5.5 11.93 11.5 Inf STEMI RMWA EF57% 1.7
162 >50.000 4.6 6.99 14.5 Inf STEMI RMWA EF43% 1.3
215 12444 8.7 1.74 16.6 Antroseptal STEMIRMWA EF35% 2.5
1812 >50.000 4.3 3.48 12 Inf STEMI RMWA EF34% 2.8
87 >50.000 7.3 2.68 14.1 Ant STEMI RMWA EF45% 1.8
55 436 7.1 1.25 12 Antroseptal STEMIRMWA EF60% 4.3
101 3375 9.6 0.49 13.2 Inf STEMI RMWA EF40% 4.2
116 11206 5.2 1.43 12.8 Inf STEMI RMWA EF56% 3.5
168 2859 5 2.43 14.2 Anteroinferior STEMIRMWA EF45% 3
156 74 11.3 3.03 12.8 Ant STEMI RMWA EF54% 5
766 >50.000 8.1 3.53 12.9 Inf STEMI RMWA EF50% 4.5
143 36 6 2.72 13 Inf STEMI RMWA EF35% 3.5
205 9905 6.2 2.38 14.3 Ant STEMI RMWA EF44% 4.4
123 31 5.8 0.47 16.5 Ant STEMI RMWA EF43% 2.5
119 10914 5.3 0.73 13.4 Ant STEMI RMWA EF55% 2.3
195 8 5.6 2 12.8 Inf STEMI RMWA EF52% 1.9
625 27 8.2 1.67 13.8 Inf STEMI RMWA EF58% 2.6
258 15322 10.7 0.37 15.5 Inf STEMI RMWA EF57% 3
175 22761 4.8 1.32 14 Ant STEMI RMWA EF40% 2.1
132 17154 6.5 3.94 14.1 Inf STEMI No RMWA EF65% 3.5
217 41444 6.7 0.4 13.6 Inf STEMI RMWA EF38% 2
97 2238 6.2 3.04 12 Inf STEMI RMWA EF42% 2.7
91 2556 9.6 1.29 16.1 Ant STEMI RMWA EF57% 3.9
44 >50.000 11.2 1.89 16.6 Antroseptal STEMIRMWA EF43% 3.2
220 <6 7 0.69 15.1 Antrolateral STEMI RMWA EF35% 2.1
137 7099 7.6 0.8 16.4 Inf STEMI RMWA EF62% 1.9
360 421 5.7 0.07 13.3 Inf STEMI RMWA EF60% 3.7
77 1250 4.9 4.91 14.3 Antrolateral STEMI RMWA EF53% 3.7
46 11519 5.2 2.13 14.9 Inf STEMI RMWA EF50% 2.9
